| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 25,000 shares ($312K) |
| 05 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Recorlev net revenue increased 93% year-over-year to more than $71 million |
| 04 Nov 2026 |
Form 4: Pieper Steven, See Remarks
Sold 5,000 shares ($51.2K) |
| 04 Nov 2026 |
Form 4: Hecht Beth, See Remarks
Sold 25,000 shares ($256K) |
| 04 Nov 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 15,000 shares ($153K) |
| 04 Nov 2026 |
Form 4: Taddese Menassie, Director
Received 22,365 shares as a grant or award · Disposed of 31,499 Stock Option (Right to Buy) (Grant/Award Acquisition) ($320K) |
| 04 Nov 2026 |
Form 3: Taddese Menassie, Director
No securities owned |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 14 Oct 2026 |
8-K: Other Events
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the “Company”), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey ... |
| 02 Oct 2026 |
Form 4: Pieper Steven, See Remarks
Sold 5,000 shares ($47K) |
| 02 Oct 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 15,000 shares ($141K) |
| 02 Oct 2026 |
Form 4: Hecht Beth, See Remarks
Sold 16,666 shares ($157K) |
| 01 Oct 2026 | 144 |
| 29 Sep 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 25,000 shares ($250K) |
| 28 Sep 2026 | 144 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved. Today’s Agenda 2 1 Welcome & Introductions Allison Wey — SVP, Investor Relations 2 Becoming the Next Great Biopharmaceutical Company John Shannon – Chairman and Chief... |
Loading...